<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04198168</url>
  </required_header>
  <id_info>
    <org_study_id>1-10-72-75-19</org_study_id>
    <nct_id>NCT04198168</nct_id>
  </id_info>
  <brief_title>The Predictive Performance of Renal Ultrasound on Changes in Renal Clearance</brief_title>
  <official_title>The Predictive Performance of Renal Ultrasonographic Perfusion Measures on Changes in Renal Clearance in Response to Fluid Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will examine the ability of renal ultrasound (Doppler and Contrast Enhanced
      Ultrasound (CEUS)) in distinguishing ICU patients who exhibit increases in glomerular
      filtration rate (GFR) in response to fluid loading, from those for whom fluid loading is
      without benefit of directly harmful.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will examine the ability of renal ultrasound (Doppler and Contrast Enhanced
      Ultrasound (CEUS)) in distinguishing ICU patients who exhibit increases in GFR in response to
      fluid loading, from those for whom fluid loading is without benefit of directly harmful.

      Patients available for inclusion will receive a baseline administration of Tc-99-DTPA for
      precise determination of GFR/renal function by blood and urine samples.

      Baseline values of ultrasound measures will be obtained, including renal arterial, renal
      venous, portal venous and hepatic venous Doppler measures and renal contrast enhanced
      ultrasound (CEUS) will also be recorded.

      After two hours, baseline values of GFR are finished. The patient is then exposed to passive
      leg raising and ultrasound measures are repeated, including renal arterial, renal venous,
      portal venous and hepatic venous Doppler measures.

      The participant then receives a standardised fluid bolus of 7 ml/kg (ideal body weight) Once
      the fluid bolus administration is complete, renal ultrasound is repeated, including renal
      arterial, renal venous, portal venous, hepatic venous Doppler measures and renal CEUS.

      Follow-up determination of GFR/renal function based on Tc-99-DTPA after fluid therapy is
      repeated with blood and urine samples.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in renal function in response to a standardised fluid bolus.</measure>
    <time_frame>6 hours</time_frame>
    <description>Renal function is measures as Tc-99-Diethylenetriaminepentaacetic acid (DTPA) clearance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal venous flow classification</measure>
    <time_frame>6 hours</time_frame>
    <description>normal - abnormal (pulsatile/biphasic/monophasic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal venous impedance index</measure>
    <time_frame>6 hours</time_frame>
    <description>(maximum flow velocity - minimum diastolic flow velocity) / maximum flow velocity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal venous stasis index</measure>
    <time_frame>6 hours</time_frame>
    <description>(index cardiac cycle time - venous flow time) / index cardiac cycle time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal arterial resistive index</measure>
    <time_frame>6 hours</time_frame>
    <description>(maximum flow velocity - minimum diastolic flow velocity) / maximum flow velocity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Portal venous pulsatility fraction</measure>
    <time_frame>6 hours</time_frame>
    <description>(maximum flow velocity - minimum diastolic flow velocity) / maximum flow velocity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast enhanced ultrasound 1</measure>
    <time_frame>6 hours</time_frame>
    <description>Mean transit time (mTT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast enhanced ultrasound 2</measure>
    <time_frame>6 hours</time_frame>
    <description>Perfusion Index (PI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast enhanced ultrasound 3</measure>
    <time_frame>6 hours</time_frame>
    <description>Relative Blood Volume (rBV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast enhanced ultrasound 4</measure>
    <time_frame>6 hours</time_frame>
    <description>Wash-in Rate (WiR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast enhanced ultrasound 5</measure>
    <time_frame>6 hours</time_frame>
    <description>Quality Of Fit (QOF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuous recordings of hemodynamic variables 1</measure>
    <time_frame>6 hours</time_frame>
    <description>arterial pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuous recordings of hemodynamic variables 2</measure>
    <time_frame>6 hours</time_frame>
    <description>Central venous pressure</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>Hypoperfusion</condition>
  <condition>Fluid Overload</condition>
  <arm_group>
    <arm_group_label>ICU patients</arm_group_label>
    <description>ICU patients who are assessed by their attending physician as having need for fluid therapy and are planned to receive IV crystalloid fluid due to oliguria and/or to improve GFR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV crystalloid fluid bolus</intervention_name>
    <description>The participant receives IV fluid as a standardised bolus of 7 ml/kg (ideal body weight).</description>
    <arm_group_label>ICU patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients admitted to the ICU at Aarhus University Hospital
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients â‰¥ 18 years admitted to the ICU, Aarhus University Hospital.

          -  Patients who are assessed by their attending physician as having need for fluid
             therapy.

        Exclusion Criteria:

          -  Insufficient ultrasound imaging of the kidneys.

          -  Pregnancy.

          -  Intolerance to any ultrasound contrast agent or isotopes, including intolerance for
             human albumin.

          -  Prior enrolment in a conflicting research study.

          -  Known morphological kidney disease.

          -  Need for dialysis.

          -  Need for extracorporeal membrane oxygenation (ECMO).

          -  Prior participation.

          -  Severe pulmonary hypertension (systolic pulmonary pressure &gt; 90 mmHg)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Johan F Hermansen, MD</last_name>
    <phone>+ 45 50 73 63 22</phone>
    <email>johanfhermansen@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Juhl-Olsen, MD, PhD</last_name>
    <phone>+ 45 30 91 10 62</phone>
    <email>peterjuhlolsen@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital, Department of Anaesthesiology</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan F Hermansen, MD</last_name>
      <phone>+ 45 50 73 63 22</phone>
      <email>johanfhermansen@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Peter Juhl-Olsen, MD, PhD</last_name>
      <phone>+ 45 30 91 10 62</phone>
      <email>peterjuhlolsen@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 8, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Johan Fridolf Hermansen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Ultrasound</keyword>
  <keyword>Renal perfusion</keyword>
  <keyword>Fluid treatment</keyword>
  <keyword>Venous congestion</keyword>
  <keyword>Renal function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

